Erratum to "Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples" (DOI:10.1016/j.diagmicrobio.2008.04.001);Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 4, 2008, Pages 415-420

  Daniel, Hubert Darius J ^a   Chandy, George M ^a   Abraham, Priya ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Hepatitis C virus RNA; In house real time RT PCR; Quantitation

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; VIRUS DETECTION; VIRUS LOAD; VIRUS TITRATION; WORLD HEALTH ORGANIZATION;

EID: 47049120665     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.10.009     Document Type: Erratum

References (22)

1. Al-Soud W.A., and Radstrom P. Purification and characterization of PCR-inhibitory components in blood cells. J. Clin. Microbiol. 39 (2001) 485-493
2. Barrera J.M., Francis B., Ercilla G., Nelles M., Achord D., Darner J., and Lee S.R. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 68 (1995) 15-18
3. Bukh J., Purcell R.H., and Miller R.H. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 187-191
4. Castelain S., Descamps V., Thibault V., Francois C., Bonte D., Morel V., Izopet J., Capron D., Zawadzki P., and Duverlie G. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J. Clin. Virol. 31 (2004) 227-234
5. Glynn S.A., Wright D.J., Kleinman S.H., Hirschkorn D., Tu Y., Heldebrant C., Smith R., Giachetti C., Gallarda J., and Busch M.P. Dynamics of viremia in early hepatitis C virus infection. Transfusion 45 (2005) 994-1002
6. Grant P.R., Garson J.A., Tedder R.S., Chan P.K., Tam J.S., and Sung J.J. Detection of SARS Coronavirus in plasma by real-time RT-PCR. N. Engl. J. Med. 349 (2003) 2468-2469
7. Guichon A., Chiparelli H., Martinez A., Rodriguez C., Trento A., Russi J.C., and Carballal G. Evaluation of a new NASBA assay for the qualitative detection of hepatitis C virus based on the NucliSens Basic Kit reagents. J. Clin. Virol. 29 (2004) 84-91
8. Harris K.A., and Teo C.G. Diversity of hepatitis C virus quasispecies evaluated by denaturing gradient gel electrophoresis. Clin. Diagn. Lab. Immunol. 8 (2001) 62-73
9. Kim T.H., Kim K.A., Lim Y.S., Gwak G.Y., Yoon J.H., Kang G.H., and Lee H.S. Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. Intervirology 48 (2005) 230-238
10. McHutchison J., Blatt L., Sedghi-Vaziri A., Russell J., Schmid P., and Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?. J. Hepatol. 29 (1998) 362-368
11. Neumann A.U., Lam N.P., Dahari H., Davidian M., Wiley T.E., Mika B.P., Perelson A.S., and Layden T.J. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182 (2000) 28-35
12. NIH. National Institutes of Health Consensus Development Conference statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 123 (2002) 2082-2099
13. OCABR. Validation of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus (HCV) RNA in plasma pools. EDQM: OCABR of biological substances 2001, Council Directive 89/391/EEC (2001)
14. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
15. Radhakrishnan S., Abraham P., Raghuraman S., John G.T., Thomas P.P., Jacob C.K., and Sridharan G. Role of molecular techniques in the detection of HBV DNA & HCV RNA among renal transplant recipients in India. Indian J. Med. Res. 111 (2000) 204-211
16. Rigopoulou E.I., Stefanidis I., Liaskos C., Zervou E.K., Rizos C., Mina P., Zachou K., Syrganis C., Patsidis E., Kyriakopoulos G., Sdrakas L., Tsianas N., and Dalekos G.N. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J. Clin. Virol. 34 (2005) 81-85
17. Roth W.K., Weber M., and Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 353 (1999) 359-363
18. Saldanha J. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J. Clin. Virol. 20 (2001) 7-13
19. Saldanha J., Heath A., Lelie N., Pisani G., Nubling M., and Yu M. Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. Vox Sang. 78 (2000) 217-224
20. Sarrazin C., Gartner B.C., Sizmann D., Babiel R., Mihm U., Hofmann W.P., von Wagner M., and Zeuzem S. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J. Clin. Microbiol. 44 (2006) 729-737
21. Tashkandy M.A., Khodari Y.A., Ibrahim A.M., Dhafar K.O., Gazzaz Z.J., and Azab B.A. Evaluation of the available anti-HCV antibody detection tests and RT-PCR assay in the diagnosis of hepatitis C virus infection. Saudi. J. Kidney. Dis. Transpl. 18 (2007) 523-531
22. WHO. Hepatitis C: global prevalence. Wkly. Epidemiol. Rec. 72 (1997) 341-344